About Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200
Debt
Debt-to-Equity Ratio0.28%
Current Ratio3.89%
Quick Ratio3.89%
Price-To-Earnings
Trailing P/E Ratio-15.21
Forward P/E Ratio-14.60
P/E GrowthN/A
Sales & Book Value
Annual Sales$21.34 million
Price / Sales89.58
Cash FlowN/A
Price / CashN/A
Book Value$5.28 per share
Price / Book7.58
Profitability
EPS (Most Recent Fiscal Year)($2.63)
Net Income$-91,400,000.00
Net Margins-250.93%
Return on Equity-62.82%
Return on Assets-33.04%
Miscellaneous
Employees159
Outstanding Shares47,780,000
Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions
What is Arena Pharmaceuticals' stock symbol?
Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."
When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?
Arena Pharmaceuticals's stock reverse split before market open on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Arena Pharmaceuticals' earnings last quarter?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted its quarterly earnings results on Wednesday, March, 14th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.65) by $0.30. The biopharmaceutical company earned $15.40 million during the quarter, compared to analyst estimates of $5.75 million. Arena Pharmaceuticals had a negative return on equity of 62.82% and a negative net margin of 250.93%. Arena Pharmaceuticals's revenue was down 77.8% on a year-over-year basis. During the same quarter last year, the business posted $1.60 earnings per share. View Arena Pharmaceuticals' Earnings History.
When is Arena Pharmaceuticals' next earnings date?
What price target have analysts set for ARNA?
7 analysts have issued 12 month price objectives for Arena Pharmaceuticals' stock. Their predictions range from $44.00 to $79.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $58.00 in the next twelve months. View Analyst Ratings for Arena Pharmaceuticals.
What are Wall Street analysts saying about Arena Pharmaceuticals stock?
Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
- 1. Needham & Company LLC analysts commented, "Arena mgmt provided a corporate update today in a 4Q17 conference call. Mgmt reiterated guidance for top-line results from etrasimod Phase 2 trial in Ulcerative Colitis (UC) later this month. Preclinical and Phase 1 data suggest the drug has the potential for differentiation in the S1P receptor modulator space. We await outcome, maintaining HOLD. Mgmt also discussed ralinepag Phase 3 trial design in Pulmonary Arterial Hypertension (PAH). Three trials are planned, two of which mgmt believes are independently sufficient for regulatory approval. Mgmt plans to provide more details around cost and time to completion mid-2018 after protocols are finalized." (3/14/2018)
- 2. According to Zacks Investment Research, "Arena’s only approved product is Belviq, used for chronic weight management. Though it was the first obesity drug to be approved by the FDA in over a decade, is yet to impress with its performance. However, the company’s partnership agreements and efforts to improve the performance of the drug are impressive. We are also encouraged by the company’s cost-reduction initiatives to streamline the organization to support its development programs. Shares of the company have outperformed the industry in the last one year. On the flip side, Arena’s pipeline consists of early-to-mid stage candidates, still several years from commercialization. Plus, competition remains intense in the obesity market with both branded and generic players. " (3/9/2018)
- 3. Cantor Fitzgerald analysts commented, "KOL event could fill in some important blank spaces. ARNA will host a lunch event on January 29 (12:30-1:30 pm) in NYC with two physician consultants to discuss modulators of S1P receptors and etrasimod, specifically. We believe the event could be helpful for investors as it relates to understanding important pharmacokinetic and pharmacodynamic properties of the drug candidate that we highlighted in a recent research report (here)." (1/17/2018)
Are investors shorting Arena Pharmaceuticals?
Arena Pharmaceuticals saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 3,192,659 shares, an increase of 71.8% from the March 15th total of 1,858,178 shares. Based on an average trading volume of 4,246,081 shares, the short-interest ratio is presently 0.8 days. Approximately 6.7% of the company's shares are sold short.
Who are some of Arena Pharmaceuticals' key competitors?
Some companies that are related to Arena Pharmaceuticals include Alkermes (ALKS), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Galápagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN) and GW Pharmaceuticals (GWPH).
Who are Arena Pharmaceuticals' key executives?
Arena Pharmaceuticals' management team includes the folowing people:
- Tina Susan Nova Ph.D., Independent Chairman of the Board (Age 63)
- Amit D. Munshi, President, Chief Executive Officer, Director (Age 49)
- Kevin R. Lind, Chief Financial Officer, Executive Vice President (Age 41)
- Steven W. Spector J.D., Executive Vice President, General Counsel, Secretary (Age 52)
- Vincent Aurentz, Executive Vice President and Chief Business Officer (Age 49)
- Preston S. Klassen M.D., Executive Vice President - Research & Development, Chief Medical Officer (Age 48)
- Jennifer Jarrett, Director (Age 46)
- Scott H. Bice J.D., Independent Director (Age 74)
- Jayson Dallas M.D., Independent Director (Age 49)
- Oliver S. Fetzer Ph.D., Independent Director (Age 52)
Has Arena Pharmaceuticals been receiving favorable news coverage?
News headlines about ARNA stock have trended positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Arena Pharmaceuticals earned a daily sentiment score of 0.35 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 48.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Arena Pharmaceuticals' major shareholders?
Arena Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (10.92%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Christine Anna White and Steven W Spector. View Institutional Ownership Trends for Arena Pharmaceuticals.
How do I buy shares of Arena Pharmaceuticals?
Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arena Pharmaceuticals' stock price today?
One share of ARNA stock can currently be purchased for approximately $40.01.
How big of a company is Arena Pharmaceuticals?
Arena Pharmaceuticals has a market capitalization of $1.90 billion and generates $21.34 million in revenue each year. The biopharmaceutical company earns $-91,400,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Arena Pharmaceuticals employs 159 workers across the globe.
How can I contact Arena Pharmaceuticals?
Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]
MarketBeat Community Rating for Arena Pharmaceuticals (ARNA)
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Arena Pharmaceuticals (NASDAQ:ARNA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Arena Pharmaceuticals in the last 12 months. Their average twelve-month price target is $58.00, suggesting that the stock has a possible upside of 44.96%. The high price target for ARNA is $79.00 and the low price target for ARNA is $44.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
Consensus Rating: | Buy | Buy | Buy | Buy |
Consensus Rating Score: | 3.00 | 3.00 | 2.88 | 2.71 |
Ratings Breakdown: | 0 Sell Rating(s) 0 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 0 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 1 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 2 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s) |
Consensus Price Target: | $58.00 | $58.00 | $41.1429 | $38.8333 |
Price Target Upside: | 44.96% upside | 45.91% upside | 21.44% upside | 54.78% upside |
Arena Pharmaceuticals (NASDAQ:ARNA) Consensus Price Target History

Arena Pharmaceuticals (NASDAQ:ARNA) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Arena Pharmaceuticals (NASDAQ:ARNA) Dividend History by Quarter
Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
---|
(Data available from 1/1/2013 forward)
Arena Pharmaceuticals (NASDAQ ARNA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.88%
Institutional Ownership Percentage: 60.03%
Arena Pharmaceuticals (NASDAQ ARNA) Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
4/16/2018 | Steven W Spector | EVP | Sell | 30,001 | $34.57 | $1,037,134.57 | 34,691 | |
5/12/2017 | Amit Munshi | Insider | Buy | 25,000 | $1.19 | $29,750.00 | 76,875 | |
4/26/2017 | Amit Munshi | Insider | Buy | 50,000 | $1.41 | $70,500.00 | 1,875 | |
6/13/2016 | Christine Anna White | Director | Sell | 18,728 | $1.99 | $37,268.72 | 85,529 | |
3/30/2015 | Randall E Woods | Director | Sell | 76,268 | $4.49 | $342,443.32 | | |
3/17/2015 | Steven W Spector | EVP | Sell | 70,000 | $5.00 | $350,000.00 | | |
1/8/2015 | Steven W Spector | EVP | Sell | 45,000 | $6.26 | $281,700.00 | | |
1/7/2015 | William R Shanahan Jr | SVP | Sell | 50,000 | $5.49 | $274,500.00 | | |
7/1/2014 | Jack Lief | CEO | Sell | 223,525 | $5.85 | $1,307,621.25 | | |
6/27/2014 | Donald D Belcher | Director | Sell | 2,473 | $5.85 | $14,467.05 | | |
5/6/2014 | Donald Belcher | Director | Sell | 4,176 | $7.00 | $29,232.00 | 68,728 | |
4/22/2014 | Harry Hixson, Jr. | Director | Sell | 36,900 | $6.31 | $232,839.00 | 82,876 | |
4/14/2014 | Tina Susan Nova | Director | Sell | 35,000 | $6.22 | $217,700.00 | 18,728 | |
4/1/2014 | Donald Belcher | Director | Sell | 1,905 | $6.45 | $12,287.25 | 68,728 | |
4/1/2014 | William Shanahan, Jr. | SVP | Sell | 60,000 | $6.37 | $382,200.00 | 35,000 | |
3/4/2014 | Steven Spector | EVP | Sell | 25,000 | $7.01 | $175,250.00 | 101,794 | |
1/17/2014 | Jack Lief | CEO | Sell | 100,000 | $7.81 | $781,000.00 | 583,704 | |
1/10/2014 | Dominic Behan | EVP | Sell | 33,332 | $6.25 | $208,325.00 | 483,000 | |
9/10/2013 | Dominic P Behan | EVP | Sell | 200,000 | $6.31 | $1,262,000.00 | | |
9/5/2013 | Steven W Spector | EVP | Sell | 20,000 | $6.54 | $130,800.00 | | |
5/21/2013 | Craig Michael Audet | SVP | Sell | 83,750 | $8.00 | $670,000.00 | | |
(Data available from 1/1/2013 forward)
Arena Pharmaceuticals (NASDAQ ARNA) News Headlines
Source: |
|
Date | Headline |
---|
 | $1.01 Million in Sales Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter www.americanbankingnews.com - April 21 at 4:40 AM |
 | Arena Pharmaceuticals (ARNA) Receives New Coverage from Analysts at Citigroup www.americanbankingnews.com - April 20 at 3:01 PM |
 | Arena Pharmaceuticals (ARNA) Rating Increased to Hold at BidaskClub www.americanbankingnews.com - April 20 at 11:55 AM |
 | Arena Pharmaceuticals (ARNA) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - April 20 at 7:46 AM |
 | Q2 2018 Biotech Catalyst Watchlist: Phase 2 Clinical Trials seekingalpha.com - April 19 at 4:13 PM |
 | Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) to Announce -$0.70 EPS www.americanbankingnews.com - April 19 at 9:07 AM |
 | Arena Pharmaceuticals, Inc. (ARNA) EVP Sells $1,037,134.57 in Stock www.americanbankingnews.com - April 18 at 7:13 PM |
 | Arena Pharmaceuticals, Inc. (ARNA) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - April 18 at 9:07 AM |
 | Arena CEO: We have two great assets and are trying to bui... finance.yahoo.com - April 17 at 4:13 PM |
 | Arena Pharmaceuticals (ARNA) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - April 17 at 11:05 AM |
 | Arena Pharmaceuticals (ARNA) Rating Lowered to Sell at BidaskClub www.americanbankingnews.com - April 16 at 9:16 PM |
 | Arena Pharmaceuticals, Inc. (ARNA) Sees Significant Increase in Short Interest www.americanbankingnews.com - April 14 at 1:40 AM |
 | Arena Pharmaceuticals (ARNA) Up 7% Since Earnings Report: Can It Continue? finance.yahoo.com - April 13 at 4:08 PM |
 | Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting finance.yahoo.com - April 12 at 10:54 AM |
 | This $3 Medical Device Stock be Worth $9-14 with Impending Product Launch finance.yahoo.com - April 5 at 8:24 AM |
 | Brokerages Anticipate Arena Pharmaceuticals, Inc. (ARNA) Will Announce Quarterly Sales of $1.01 Million www.americanbankingnews.com - April 4 at 4:18 AM |
 | Arena Pharmaceuticals, Inc. (ARNA) Expected to Post Earnings of -$0.70 Per Share www.americanbankingnews.com - April 2 at 7:22 AM |
 | Arena Pharmaceuticals (ARNA) Upgraded to "Outperform" by Wells Fargo www.americanbankingnews.com - March 31 at 12:12 AM |
 | Arena Pharmaceuticals Inc (NASDAQ:ARNA): Earnings Growth Remains Elusive finance.yahoo.com - March 29 at 4:01 PM |
 | Arena Pharmaceuticals (ARNA) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - March 29 at 12:45 PM |
 | BidaskClub Lowers Arena Pharmaceuticals (ARNA) to Buy www.americanbankingnews.com - March 28 at 11:56 AM |
 | Arena Pharmaceuticals (ARNA) Earns "Buy" Rating from Cantor Fitzgerald www.americanbankingnews.com - March 27 at 10:23 PM |
 | Arena Pharmaceuticals' (ARNA) "Positive" Rating Reaffirmed at Leerink Swann www.americanbankingnews.com - March 27 at 6:16 PM |
 | Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares finance.yahoo.com - March 27 at 10:12 AM |
 | Arena Pharmaceuticals (ARNA) Upgraded at BidaskClub www.americanbankingnews.com - March 26 at 8:58 AM |
 | Arena Pharmaceuticals (ARNA) Cut to Buy at BidaskClub www.americanbankingnews.com - March 25 at 12:50 AM |
 | Citigroup Boosts Arena Pharmaceuticals (ARNA) Price Target to $55.00 www.americanbankingnews.com - March 24 at 9:28 PM |
 | 3 Biotech Stocks That Skyrocketed This Week: Are They Buys? finance.yahoo.com - March 24 at 4:28 PM |
 | Arena Pharmaceuticals (ARNA) Downgraded by BidaskClub to Sell www.americanbankingnews.com - March 24 at 1:54 PM |
 | Arena Pharmaceuticals, Inc. (ARNA) Given Average Recommendation of "Buy" by Analysts www.americanbankingnews.com - March 24 at 8:29 AM |
 | Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27 - PR Newswire (press release) www.prnewswire.com - March 24 at 8:10 AM |
 | Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27 finance.yahoo.com - March 24 at 8:09 AM |
 | Arena Pharmaceuticals (ARNA) Rating Increased to Hold at ValuEngine www.americanbankingnews.com - March 23 at 11:22 PM |
 | Arena Pharmaceuticals Takes Aim at Celgene finance.yahoo.com - March 23 at 6:24 PM |
 | One Biotech Turnaround to Watch finance.yahoo.com - March 23 at 9:37 AM |
 | Arena Raises Impressive $352 Million On Stock Offering - Seeking Alpha seekingalpha.com - March 22 at 4:13 PM |
 | Arena Pharmaceuticals (ARNA) in Focus: Stock Moves 10.7% Higher finance.yahoo.com - March 22 at 9:52 AM |
 | Leerink Swann Weighs in on Arena Pharmaceuticals, Inc.'s Q2 2018 Earnings (ARNA) www.americanbankingnews.com - March 22 at 9:34 AM |
 | Traders Purchase High Volume of Arena Pharmaceuticals Put Options (ARNA) www.americanbankingnews.com - March 22 at 7:16 AM |
 | Here's Why Arena Pharmaceuticals, Inc. Surged Again on Wednesday finance.yahoo.com - March 21 at 4:14 PM |
 | Arena Pharmaceuticals' (ARNA) "Buy" Rating Reaffirmed at Citigroup www.americanbankingnews.com - March 21 at 1:56 PM |
 | Here's Why Arena Pharmaceuticals Jumped 30% Today www.msn.com - March 21 at 10:50 AM |
 | Arena Pharma (ARNA) to Offer 7.5M Shares of Common Stock www.streetinsider.com - March 21 at 10:50 AM |
 | Arena Pharmaceuticals shares tick lower on secondary offering www.marketwatch.com - March 21 at 10:50 AM |
 | Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal finance.yahoo.com - March 21 at 10:50 AM |
 | Today’s Research Reports on Trending Tickers: Arena Pharmaceuticals and CASI Pharmaceuticals finance.yahoo.com - March 21 at 10:50 AM |
 | Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal - Nasdaq www.nasdaq.com - March 20 at 4:12 PM |
 | ARNA Soars After-hours, Remoxy Now 2 Steps Away From Approval, APLS On Watch - Nasdaq www.nasdaq.com - March 20 at 4:12 PM |
 | Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock - PR Newswire (press release) www.prnewswire.com - March 20 at 4:12 PM |
 | Arena Pharma (ARNA) to Offer 7.5M Shares of Common Stock - StreetInsider.com www.streetinsider.com - March 20 at 4:12 PM |
Arena Pharmaceuticals (NASDAQ:ARNA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Arena Pharmaceuticals (NASDAQ:ARNA) Income Statement, Balance Sheet and Cash Flow Statement
Arena Pharmaceuticals (NASDAQ ARNA) Stock Chart for Wednesday, April, 25, 2018
Loading chart…